Gemcad 1903: Study to validate the predictive value of CYP2D6 duplications in anal cancer. Coordinador: Dr. Jaime Feliu.
Gemcad 1701 – BEYOND: Phase II clinical trial to evaluate the efficacy of FOLFIRI + panitumumab in second-line treatment of metastatic colorectal cancer patients with non-mutated RAS who received FOLFOX + panitumumab first line treatment. Coordinador: Dr. Aparicio
GEMCAD 1603 – OPALO: “Phase II study to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with unresectable wild type RAS/BRAF metastatic colorectal cancer: the OPALO study”.
GEMCAD 1602 – AVEVAC: “Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated MSS metastatic colorectal cancer patients”.
Gemcad 1601 – PIER: Preoperative Induction Therapy with 12 weeks of panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third with clear mesorectal fascia PIER Trial. Coordinador: Dr. Carlos Fernandez Martos
GEMCAD 1402 – RIA: “Phase II randomized trial of induction FOLFOX vs FOLFOX plus aflibercet followed by CRT in high risk rectal adenocarcinoma”: Finalizado el reclutamiento. Pacientes reclutado 180. En fase de seguimiento. Primer análisis de endpoint primario último trimestre 2017.
GEMCAD 1401: "Observational study to evaluate the effectiveness of the initial deferred vs use of targeted therapies, in metastatic colon cancer ": Coordinadores: Dres. Maurel, Feliu, García-Albéniz.
GEMCAD 1006 – AVAMET: "Phase IV Study, multicenter, to evaluate the correlation of overall objective response as assessed by RECIST v1.1 conventional imaging techniques, with morphologic response by CT and pathological response following resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with Xeloxl ". Patients recruited: n=83.
GEMCAD 1003: “Estudio de inducción con gemcitabina-RDT y erlotinib enpacientes con c.páncreas y enfermedad resecable”. Patients recruited: n=27.
GEMCAD 1002 – POSIBA: “Ensayo clínico fase II de un solo brazo, multicéntrico y prospectivo para la evaluación de biomarcadores en pacientes con cáncer colorrectal avanzado y/o metastásico con gen KRAS/NRAS no mutado tratados con quimioterapia más cetuximab bisemanal como terapia de primera línea”: Patients recruited: n=221.
GEMCAD 1001: "Translational retrospective study validating a gene signature predictive of response in rectal cancer". Patients recruited: n=193.
GEMCAD 0903 – PULSE: "Open label phase II to evaluate potential predictive tumor markers in patients with metastatic colorectal cancer with KRAS wild-type tumors treated with FOLFOX 6m and panitumumab as first-line". Patients recruited: n=78.
GEMCAD 0902 – VITAL: "Phase II study to evaluate the efficacy and safety of chemoradiotherapy with 5-fluorouracil, panitumumab as mitomycin C treatment and anal squamous cell carcinoma ". Patients recruited: n=58.
GEMCAD 0901 – BECOX: "Open Studio, nonrandomized, multicenter, a phase II, for evauar the efficacy and safety of bevacizumab in combination with capecitabine and oxaliplatin, como primera línea de tratamiento en pacientes ancianos con adenocarcinoma colorrectal metastásico indicados para recibir tratamiento poliquimioterápico”. Patients recruited: n=69.
GEMCAD 0802: "Phase II Study, of the combination of oxaliplatin and Sorafenib in patients with gastric adenocarcinoma of the gastroesophageal junction or locally advanced or metastatic, en progresión tras un esquema basado en cisplatino”. Patients recruited: n=41.
GEMCAD 0801: "Phase II Study, multicenter, open, nonrandomized, de quimioterapia neoadyuvante con uso selectivo de radioterapia en pacientes con cáncer de recto de riesgo intermedio definidos con resonancia magnética”. Patients recruited: n=46.
GEMCAD 0701: "Phase I Study, study evaluating the safety and efficacy of the combination of Sorafenib (BAY 43-9006), Gemcitabine and concurrent radiotherapy in the treatment of patients with locally advanced pancreatic adenocarcinoma ". Patients recruited: n=12.